Filing Details
- Accession Number:
- 0001246360-11-003275
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-08-04 20:20:09
- Reporting Period:
- 2011-08-01
- Filing Date:
- 2011-08-04
- Accepted Time:
- 2011-08-04 20:20:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
64670 | Medtronic Inc | MDT | Electromedical & Electrotherapeutic Apparatus (3845) | 410793183 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1379946 | J Christopher Oconnell | 710 Medtronic Pkwy Ms Lc300 Minneapolis MN 55432 | Evp & Grouppres Restora Therap | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-08-01 | 21,044 | $0.00 | 103,218 | No | 4 | A | Direct | |
Common Stock | Disposition | 2011-08-04 | 4,000 | $33.98 | 99,218 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Acquisiton | 2011-08-01 | 84,060 | $0.00 | 84,060 | $34.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
84,060 | 2012-08-01 | 2021-08-01 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,461 | Indirect | ESOP |
Footnotes
- This balance increased by 273.859 shares due to exempt transactions such as dividend reinvestment.
- These Restricted Stock Units lapse 100% on the third anniversary of the grant date if the company's cumulative diluted earnings per share growth during the 36 month period ending on the last day of the company's fiscal year 2014 equals or exceeds a 3% compound annual growth rate, as determined by the compensation committee.
- These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.
- These shares were sold under a 10b5-1 plan.